Creating a TB lab protocol for anonymous external quality assessments

A well-written protocol for anonymous external quality assessment (EQA) is more than a procedural formality; it is the backbone of credibility for any tuberculosis laboratory. In Australia, where the annual TB notification rate is among the lowest in the world yet remains significant in remote and migrant populations, the protocols that govern blinded panel testing often decide whether a quiet outbreak is caught early or missed entirely. The GLI Quality Tool frames this work through a four-phase roadmap built around twelve Quality Systems Essentials, giving laboratories a common scaffolding for designing, documenting and refining their EQA practice.

This article walks through the practical steps for drafting a TB laboratory protocol that handles external quality assessment samples with full anonymity while still meeting accreditation expectations such as those set by the National Association of Testing Authorities (NATA) and the National Pathology Accreditation Advisory Council (NPAAC). It is written for laboratory managers, senior scientists and quality officers in metropolitan and regional settings alike, from Perth and Adelaide to Townsville and Hobart.

Understanding the purpose of anonymous EQA panels

Anonymous EQA panels are proficiency-testing specimens deliberately stripped of identifying details so that staff cannot recognise whether a tube or slide is from a real patient or an external programme. The goal is to measure what the laboratory actually does on a routine day, not what it can do when it knows it is being watched. In Australian reference centres such as PathWest Laboratory Medicine Western Australia or the Victorian Infectious Diseases Reference Laboratory (VIDRL) in Melbourne, panels arrive under strict chain-of-custody arrangements and are logged through a parallel EQA register to keep them segregated from clinical work.

Anonymity in this context is not a courtesy but a methodological safeguard. When an analyst recognises a panel item, conscious or unconscious bias can distort critical calls such as grading a scanty smear or reporting rifampicin resistance. Australian laboratories that serve communities in the Torres Strait and the Anangu Pitjantjatjara Yankunytjatjara Lands rely heavily on accurate smear microscopy results, so a protocol that protects blinding protects the patient downstream of the laboratory report.

Mapping roles and responsibilities within the laboratory

Every EQA protocol needs a clear responsibility matrix before any sample is opened. The minimum roles typically include a designated EQA coordinator who is the single recipient of correspondence from the provider, a receiving officer who handles unpacking and integrity checks, the technical staff who perform the analyses blind, and a quality manager who reviews results before submission. In larger multi-site networks such as NSW Health Pathology, these responsibilities are often split across ICPMR in Westmead, the John Hunter Hospital laboratory in Newcastle and satellite sites in Dubbo and Broken Hill.

In Australia, role assignments must be supported by evidence of competency. NATA ISO 15189 assessments look for signed training records, observed competency assessments and continuing professional development activities recorded by bodies such as the Australian Institute of Medical Scientists (AIMS) or the Royal College of Pathologists of Australasia (RCPA). The protocol should therefore name each role, the training prerequisites required, and the back-up arrangements that apply when key staff are on leave in remote settings where locum cover is rare.

Designing the workflow for sample reception and de-identification

The reception workflow is the most fragile part of any EQA protocol because mistakes here can compromise blinding for the rest of the panel. The protocol should describe how shipments are received in the designated unpacking area, inspected for tamper-evident seals, and matched against the provider's dispatch list without removing the anonymous labelling. Biological substances Category B packaging rules apply, and Australian couriers servicing the Northern Territory or far north Queensland routinely use IATA-compliant secondary containers.

Once accepted, panels must be entered into a separate EQA register that is not visible from the routine laboratory information system. Each item receives a unique protocol-defined identifier, and physical storage follows the same temperature, security and chain-of-custody conditions used for clinical specimens. In laboratories that share platforms between campuses, such as the MGIT workflow between Royal Adelaide Hospital and the Women's and Children's Hospital, the de-identified identifiers are what allow panels to move between sites without exposing their provenance.

Selecting reagents, equipment and analytical methods

The protocol must lock in which routine assays will be applied to the blinded samples so that EQA performance genuinely reflects patient testing. For most Australian TB laboratories this includes fluorescent auramine-rhodamine smears read at low concentration, MGIT liquid culture for mycobacterial growth, and molecular confirmation using GeneXpert MTB/RIF Ultra or Hain line-probe assays. Each assay carries acceptance criteria, lot-number documentation rules and instrument calibration checks that mirror the routine workflow exactly.

For microscopy, fluorescence-based reading remains the preferred modality in high-throughput Australian laboratories, and consistent operator competence is non-negotiable. Resources on fluorescent microscopy training can be slotted directly into induction and refresher cycles, particularly for analysts rotating through regional sites such as Cairns, Mackay or Broome where senior microscopy cover is thin. Reagent selection should reflect locally available supplies, with documented alternatives if a preferred lot is recalled.

Recording results and managing documentation

Result capture for blinded panels happens under controlled conditions, usually by the technical staff who performed the analysis and witnessed by the EQA coordinator. The protocol must state the exact reporting template to be used, the units and breakpoints to be applied for drug susceptibility, and the deadline for submission to the provider. Paper or electronic forms should be designed so that patient identifiers cannot be entered by mistake, with dropdowns limited to the EQA identifier established at reception.

Documentation must also cover record retention, archival of raw data, and audit trails. Australian laboratories often align their EQA documentation with the phase-specific checklists available through the GLI Quality Tool to ensure full coverage of the twelve Quality Systems Essentials. Master copies of the protocol, signed approval sheets, version history and superseded versions should be retained for the period required by state health department policy and by the RCPA repository of laboratory quality records.

Handling non-conformities and triggering corrective action

Even with a tightly designed protocol, things will occasionally go wrong. A panel may arrive thawed, a smear may be reported by an untrained analyst, or a result may be submitted past the deadline. The protocol should anticipate these events with a non-conformity section that defines the reporting timeline, the responsible person, and the corrective action pathway. In Australia, this is usually aligned with NPAAC requirements and AS/NZS ISO 15189 expectations for incident management.

Root cause analysis is essential, particularly when EQA outcomes deviate from consensus. Findings feed back into the protocol revision cycle, ensuring that each EQA round strengthens the system rather than exposing it. Where services span culturally diverse communities, the review should also consider whether sample handling differences between sites contributed to the error.

Reviewing, approving and continually improving the protocol

A TB EQA protocol is never a finished artefact. It should be reviewed at least annually, with explicit version control that captures every change, reviewer, and approver. The management review meeting, which Australian laboratories typically hold as part of their annual quality programme, is the natural venue for this evaluation. Inputs include EQA provider feedback summaries, internal audit findings, staff competency trends and any changes to NPAAC or RCPA guidance.

The fourth phase of the GLI Quality Tool roadmap, focused on continual improvement, is where protocol revisions are prioritised and resourced. Improvement actions might include introducing digital imaging for archived slides, expanding molecular-first reflex testing in low-incidence areas, or strengthening cultural safety training for staff engaging with First Nations patients. Each enhancement should be tested, recorded, and reflected in the next iteration of the protocol so that the document remains a living tool rather than a binder on a shelf.

Download the phase-specific checklists and user instructions inside the GLI Quality Tool and map your current EQA practice against the four-phase roadmap and the twelve Quality Systems Essentials today. The downloadable templates are designed to adapt to local contexts, including the diverse geographic and cultural settings found across Australia, so your next protocol revision can be tailored to the realities of the laboratory you work in.